Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2024-07-04 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
2024年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2024 Second Extraordinary General Meeting of Shareholders" of Lingkang Pharmaceutical Group Co., Ltd. It contains the agenda, meeting instructions, and a proposal regarding the downward adjustment of the conversion price of convertible bonds. The content is focused on the meeting agenda, voting procedures, and proposal details for shareholder approval. There are no financial statements or detailed financial performance data. The document is a set of meeting materials provided to shareholders for the Extraordinary General Meeting (EGM). According to the filing definitions, materials shared during a general meeting, including agendas and proposals, fall under AGM Information (AGM-R). Although this is an extraordinary meeting, the category AGM-R is the closest match for meeting materials. The document length is 2667 characters, which is relatively short and consistent with meeting materials rather than a full report or announcement of voting results. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-07-04 Chinese
关于子公司丙氨酰谷氨酰胺注射液新增规格获得批准文号的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the approval of a new specification for a subsidiary's pharmaceutical product by the National Medical Products Administration (国家药品监督管理局). It details the drug name, approval number, production details, and the impact on the company. The document is short (1522 characters) and serves as a regulatory announcement about product approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it contains substantive content about the approval. The document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about product approval and related information that does not fit other specific categories.
2024-07-03 Chinese
关于“灵康转债”可选择回售结果的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the results of a selective repurchase (回售) of its convertible bonds (灵康转债). It provides details such as the repurchase period, the number of bonds repurchased, the total repurchase amount including interest and tax, and the payment date. It also states the impact of the repurchase on the company and the remaining bond balance. The document is a formal disclosure of the outcome of a bond repurchase event, not a full financial report or earnings release. It fits the category of a capital or financing update, as it relates to changes in the company's capital structure through bond repurchase. The document length is 1632 characters, which is relatively short but contains substantive information about the financing activity, so it is not merely an announcement of a report publication. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-07-02 Chinese
可转债转股结果暨股份变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and the resulting changes in the company's share capital. It provides specific data on the amount of bonds converted into shares during a defined period and the updated shareholding structure. The document is relatively short (1482 characters) and focuses on share capital changes due to convertible bond conversions. This fits the category of Share Issue/Capital Change (SHA), as it details changes in share capital resulting from bond conversions into shares. It is not a full financial report, earnings release, or regulatory filing, but a specific announcement about capital changes.
2024-07-02 Chinese
关于“灵康转债”可选择回售的第三次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the optional repurchase (回售) of its convertible bonds (灵康转债). It details the repurchase price, repurchase period, payment date, and procedural instructions for bondholders. The document references regulatory rules and the bond issuance prospectus but does not contain financial statements or comprehensive financial data. It is a notification about a capital/financing event related to convertible bonds, specifically a bond repurchase option. The document length is 2118 characters, which is relatively short and focused on a specific financing update rather than a full report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-06-27 Chinese
关于“灵康转债”可选择回售的第二次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the optional repurchase (回售) of a convertible bond issued by Lingkang Pharmaceutical Group Co., Ltd. It includes specific terms such as repurchase price, repurchase period, payment date, and procedural instructions for bondholders. The content focuses on the bond repurchase event and related investor instructions rather than financial results, management changes, or regulatory certifications. The document length is 2118 characters, which is relatively short but contains substantive information about a capital market event involving convertible bonds. This fits the category of Capital/Financing Update (CAP), as it updates investors on financing activities related to convertible bonds and their repurchase options.
2024-06-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.